Abstract
MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Current Chemical Biology
Title:MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Volume: 6 Issue: 1
Author(s): Miao Ming, Xu Zhao, Zi-yi Zhao, Bo Liu and Jin-ku Bao
Affiliation:
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Abstract: MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Export Options
About this article
Cite this article as:
Ming Miao, Zhao Xu, Zhao Zi-yi, Liu Bo and Bao Jin-ku, MicroRNA Regulation of Programmed Cell Death Pathways in Cancer, Current Chemical Biology 2012; 6 (1) . https://dx.doi.org/10.2174/2212796811206010053
DOI https://dx.doi.org/10.2174/2212796811206010053 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Applications of the Receptor Mimetic Peptide Mastoparan
Current Protein & Peptide Science Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) The Impact of Molecularly Targeted Therapies Upon the Understanding of Leukemogenesis and the Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia
Current Stem Cell Research & Therapy Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
Current Pharmaceutical Biotechnology The Genus Glycosmis [Rutaceae]: A Comprehensive Review on its Phytochemical and Pharmacological Perspectives
The Natural Products Journal Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine The Functions of Polo-Like Kinases and their Relevance to Human Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations
Current Signal Transduction Therapy HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design